ClinicalTrials.gg
CompletedNCT03760848Updated Aug 22, 2019

Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Aramchol in Healthy Volunteers

A Phase 1 interventional study of Aramchol and Midazolam in Healthy, sponsored by Galmed Pharmaceuticals Ltd. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-22.

Sponsored by Galmed Pharmaceuticals Ltd · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The trial is an open-label, 2-period, single-sequence assessment of CYP3A4 inhibition by aramchol using the probe substrates midazolam and atorvastatin to assess CYP3A4 activity.

Read the detailed description

Enrolment of 16 subjects is planned. Each subject will take part in 2 study periods.

In Period 1, subjects will receive a single oral dose of 2 mg midazolam on Day 1 and a single oral dose of 40 mg atorvastatin on Day 3.

In Period 2, subjects will receive twice-daily oral doses of 300 mg aramchol (the IMP) for 18 days. During aramchol dosing, subjects will take a single dose of 2 mg midazolam in the morning on Day 10 and 40 mg atorvastatin in the morning on Day 12.

Subjects will be screened within 21 days before their first dose of study medicine. In Period 1, they will remain resident on the ward from Day -1 to Day 10. In Period 2, subjects will be admitted on Day -1 and discharged on Day 19. Subjects will attend a follow-up visit approximately 2 weeks later, on Day 33 (±2 days). There will be an interval of at least 1 day between Periods 1 and 2.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Galmed Pharmaceuticals Ltd is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male healthy volunteers.
  2. Aged 18-45 years at time of consent.
  3. A (BMI; Quetelet index) in the range 18.0-30.9.
  4. Ability to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of the entire trial.
  5. Willingness to give written consent to participate after reading and understanding the information and consent form, and after having the opportunity to discuss the trial with the investigator or his delegate.
  6. Agree to use effective as described in section 9.
  7. Agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication.
  8. Willingness to give written consent to have data entered into The Overvolunteering Prevention System (TOPS).

Exclusion criteria

Exclusion Criteria:

  1. Volunteers of East Asian descent including, but not limited to, Chinese, Japanese, Korean, Mongolian, and/or Vietnamese
  2. Be a smoker, or have smoked cigarettes or other tobacco or nicotine products in the last 12 months.
  3. abnormal history, physical findings, , or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the volunteer.
  4. (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (AP) > (ULN) at the screening visit. A repeat is allowed on one occasion for determination of eligibility.
  5. Presence of acute or chronic illness or history of chronic illness sufficient to invalidate the volunteer's participation in the trial or make it unnecessarily hazardous,
  6. Presence or history of obstructive sleep apnoea.
  7. History or presence of any disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs including gastrointestinal disorder or of oesophageal, gastric, biliary or intestinal surgery (excluding herniotomy and appendectomy).
  8. Use of anticholinergic or other drugs known to affect gastrointestinal motility during the 7 days before the first dose of trial medication.
  9. Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease, or history of any psychotic mental illness.
  10. Surgery (eg stomach bypass) or medical condition that might affect absorption of medicines.
  11. Presence or history of severe adverse reaction to any drug or a history of sensitivity to aramchol, midazolam or atorvastatin, or any in the tablets.
  12. Use of a prescription medicine or any other medicine or herbal remedy (such as St John's wort) during the 28 days before the first dose of trial medication or use of any other over-the-counter medicine, with the exception of acetaminophen (paracetamol), during the 7 days before the first dose of trial medication.
  13. Receipt of an product (including prescription medicines) as part of another clinical trial within the 3 months before first admission to this study; in the follow-up period of another clinical trial at the time of screening for this study.
  14. Presence or history of drug or alcohol abuse, or intake of more than 14 units of alcohol weekly.
  15. Blood pressure and heart rate in supine position at the screening examination outside the ranges: blood pressure 100-140 mm Hg systolic, 50-90 mm Hg diastolic; heart rate 45_90 beats/min, unless judged not clinically significant.
  16. Possibility that the volunteer will not cooperate with the requirements of the protocol.
  17. Evidence of drug abuse on urine testing.
  18. Positive test for , or .
  19. Loss of more than 400 mL blood during the 3 months before the trial, eg as a blood donor.
  20. Objection by General Practitioner (GP) to volunteer entering trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Other
    Midazolam, Atorvastatin / Aramchol, Midazolam, Atorvastatin

    Midazolam 2 mg -atorvastatin 40 mg /Aramchol 600mg -midazolam 2 mg-atorvastatin 40 mg (MA/MAA)

    Drug: Aramchol · Drug: Midazolam · Drug: Atorvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Midazolam - cmax

    Maximum plasma concentration

    Time frame: Blood samples for assay of midazolam will be taken before, and frequently up to 48 hours after each dose.

  2. Atorvastatin - cmax

    Maximum plasma concentration

    Time frame: Blood samples for assay of atorvastatin will be taken before, and frequently up to 168 hours after each dose.

  3. Midazolam - tmax

    Time of maximum plasma concentration

    Time frame: Blood samples for assay of midazolam will be taken before, and frequently up to 48 hours after each dose.

  4. Atorvastatin - tmax

    Time of maximum plasma concentration

    Time frame: Blood samples for assay of atorvastatin will be taken before, and frequently up to 168 hours after each dose.

  5. Midazolam - Area under the concentration-time curve to last measurable concentration (AUClast)

    Time frame: Blood samples for assay of midazolam will be taken before, and frequently up to 48 hours after each dose.

  6. Atorvastatin - Area under the concentration-time curve to last measurable concentration (AUClast)

    Time frame: Blood samples for assay of atorvastatin will be taken before, and frequently up to 168 hours after each dose.

  7. Midazolam - Area under the concentration-time curve extrapolated to infinite time (AUCinf)

    Time frame: Blood samples for assay of midazolam will be taken before, and frequently up to 48 hours after each dose.

  8. Atorvastatin - Area under the concentration-time curve extrapolated to infinite time (AUCinf)

    Time frame: Blood samples for assay of atorvastatin will be taken before, and frequently up to 168 hours after each dose.

  9. Midazolam - %AUCextrapinf

    Percentage of AUC that was extrapolated

    Time frame: Blood samples for assay of midazolam will be taken before, and frequently up to 48 hours after each dose.

  10. Atorvastatin - %AUCextrapinf

    Percentage of AUC that was extrapolated

    Time frame: Blood samples for assay of atorvastatin will be taken before, and frequently up to 168 hours after each dose.

  11. Midazolam - t½

    Terminal elimination half-life

    Time frame: Blood samples for assay of midazolam will be taken before, and frequently up to 48 hours after each dose.

  12. Atorvastatin - t½

    Terminal elimination half-life

    Time frame: Blood samples for assay of atorvastatin will be taken before, and frequently up to 168 hours after each dose.

  13. Midazolam - CL/F

    Clearance/fraction of dose absorbed

    Time frame: Blood samples for assay of midazolam will be taken before, and frequently up to 48 hours after each dose.

  14. Atorvastatin - CL/F

    Clearance/fraction of dose absorbed

    Time frame: Blood samples for assay of atorvastatin will be taken before, and frequently up to 168 hours after each dose.

  15. Midazolam - VZ/F

    Volume of distribution/fraction of dose absorbed

    Time frame: Blood samples for assay of midazolam will be taken before, and frequently up to 48 hours after each dose.

  16. Atorvastatin - VZ/F

    Volume of distribution/fraction of dose absorbed

    Time frame: Blood samples for assay of atorvastatin will be taken before, and frequently up to 168 hours after each dose.

  17. Midazolam - MRT

    Mean residence time

    Time frame: Blood samples for assay of midazolam will be taken before, and frequently up to 48 hours after each dose.

  18. Atorvastatin - MRT

    Mean residence time

    Time frame: Blood samples for assay of atorvastatin will be taken before, and frequently up to 168 hours after each dose.

  19. Midazolam - λz

    Terminal rate constant

    Time frame: Blood samples for assay of midazolam will be taken before, and frequently up to 48 hours after each dose.

  20. Atorvastatin - λz

    Terminal rate constant

    Time frame: Blood samples for assay of atorvastatin will be taken before, and frequently up to 168 hours after each dose.

07

Study locations

1 site
  • Hammersmith Medicines Research (HMR)
    London, NW10 7EW, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Feb 2019, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2018
First posted
Nov 30, 2018
StartActual
Nov 12, 2018
Primary completionActual
Feb 2, 2019
CompletionActual
Feb 2, 2019
Last update
Aug 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03760848
Lead sponsor
Galmed Pharmaceuticals Ltd
Collaborators
Hammersmith Medicines Research, Analyst Research Laboratories, Alderley Analytical Ltd., Diamond Pharma Services Regulatory Affairs Consultancy
Responsible party
Sponsor
First posted
Nov 30, 2018
Start date
Nov 12, 2018
Primary completion
Feb 2, 2019
Completion
Feb 2, 2019
Last update
Aug 22, 2019

Study contacts

Adeep Puri, M.D.
principal investigator · HMR

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aramchol

Start the discussion